Hiromichi Ebi

8.5k citations
87 papers · 4.0k indexed · 1 hit paper · h-index 29
Topics
Colorectal Cancer Treatments and Studies (29 papers)Lung Cancer Treatments and Mutations (27 papers)Cancer Genomics and Diagnostics (16 papers)
Partner nations
JapanUnited StatesChina

In The Last Decade

Hiromichi Ebi

84 papers receiving 4.0k citations

Hit Papers

EGFR-Mediated Reactivation of MAPK Signaling Contributes ...20122026201620212012250500750

Peers

Hiromichi Ebi
Comparison fields: 5 of 96
  • Molecular Biology 2.5k
  • Oncology 2.0k
  • Pulmonary and Respiratory Medicine 1.3k
  • Cancer Research 1.0k
  • Pathology and Forensic Medicine 662
Replace Liwei Wang with:
Liwei Wang China
Davide Melisi Italy
Mauricio Burotto United States
Alejandro D. Ricart United States
Angelo Raffaele Bianco Italy
Jan Brabender Germany
Samuel E. DePrimo United States
Samuel J. Klempner United States
Miquel Tarón Spain
Simona Lamba Italy
Hiromichi Ebi relative to Liwei Wang China Liwei Wang's profile →
Citations per field
00.5×1.7×
Liwei Wang · 1×
Citations per year

Countries citing papers authored by Hiromichi Ebi

Since Specialization
Citations

This map shows the geographic impact of Hiromichi Ebi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiromichi Ebi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiromichi Ebi more than expected).

Fields of papers citing papers by Hiromichi Ebi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiromichi Ebi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiromichi Ebi. The network helps show where Hiromichi Ebi may publish in the future.

Co-authorship network of co-authors of Hiromichi Ebi

This figure shows the co-authorship network connecting the top 25 collaborators of Hiromichi Ebi. A scholar is included among the top collaborators of Hiromichi Ebi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiromichi Ebi. Hiromichi Ebi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 3
4 3
5 40
6 5
7 6
8 92
9 146
10 85
11 108
12 11
13 136
14 174
15
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenibbreakdown →
767
16 88
17 153
18 31
19 108
20
Phase I and pharmacokinetic study of weekly docetaxel (DOC) plus irinotecan (IRN) in patients with advanced solid tumors
1

About Hiromichi Ebi

Hiromichi Ebi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 87 papers that have together received 4.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (29 papers), Lung Cancer Treatments and Mutations (27 papers) and Cancer Genomics and Diagnostics (16 papers). The work is most often cited by research in Oncology (2.0k citations), Cancer Research (1.0k citations) and Pulmonary and Respiratory Medicine (1.3k citations). Hiromichi Ebi has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Jeffrey A. Engelman, Cyril H. Benes, Seiji Yano, Ryan B. Corcoran, Mari Mino–Kenudson, Patricia Della Pelle, Jeffrey Settleman, Anthony C. Faber, Eugene Lifshits and Kenneth E. Hung. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026